Cancer Immunotherapy Principles and Practice, Second Edition: Edition 2
About this ebook
The expanded and updated second edition now spans 68 chapters, including 12 new chapters, covering major topics and innovations that have shaped the rapid development of immunotherapy and its ascension into the standard of care as first-line treatment for a growing number of disease settings. New to this edition are chapters with deeper insight into our understanding of cancer genomics and determinants of response, immunogenic cell death, cancer and stromal cell-intrinsic pathways of immune resistance, cancer immune exclusion, adoptive cell therapy, metabolomics, tumor mutation burden, immunotherapy in combination with radiation therapy, synthetic biology, and more. Complete with detailed illustrations, tables, and key points for targeted reference, Cancer Immunotherapy Principles and Practice, Second Edition is the most comprehensive and authoritative resource for scientists and clinicians looking to expand their knowledge base of this dynamic field.
Key Features:
- Offers key insights and perspectives on cancer immunology and immunotherapy treatments from renowned experts in the field
- Covers the basic principles and science behind cancer immunotherapy and tumor immunology
- Includes treatment strategies for a vast array of available immunotherapy classes and agents, such as cytokine therapies, oncolytic viruses, cancer vaccines, CAR T therapies, and combination immunotherapies
- Provides essential information on FDA-approved immunotherapies, including clinical management and outcome data related to response rates, risks, and toxicities
- Discusses special considerations for immunotherapy in the context of specific disease settings, including skin cancers, genitourinary cancers, gastrointestinal cancers, hepatocellular carcinomas, gynecologic malignancies, breast cancers, lung cancers, head and neck cancers, brain tumors, sarcomas, pediatric cancers, and treatments combined with radiation therapy
- Clarifies the complex regulatory aspects behind the development and approval of immunotherapy drugs
About the author
Lisa H. Butterfield, PhD, Professor of Medicine, Surgery, and Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA
Howard L. Kaufman, MD, FACS, Associate Director of Clinical Sciences, Chief Surgical Officer, Rutgers Cancer Institute of New Jersey; and Professor and Chief, Division of Surgical Oncology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
Francesco M. Marincola, MD, FACS, Chief Research Officer, Sidra Medical and Research Institute and Professor of Medicine, Weill-Cornell Medical College, Doha, Qatar
